CLINICAL_TRIALS
research
· 2026-01-15
Clinical Trial Update: Efficacy of INM004 in Children With STEC-HUS [Phase 3]
Summary
Phase 3 trial evaluating INM004 for efficacy in children with Shiga toxin-producing E. coli-associated Hemolytic-Uremic Syndrome is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Inmunova S.A. | Conditions: Hemolytic-Uremic Syndrome | Phase 3 | Status: RECRUITING